Target Market Small biotech and early-stage pharma players with a focus on real-world evidence, comparative cost and outcomes analysis. Evid Science’ AI-driven evidence database offers a compelling value proposition for cost-of-therapy optimization, payer discussions, and market access strategy, presenting a growth path from a lean revenue base to enterprise-scale deployments.

AI Advantage Position the platform as a scalable, speed-to-insight solution that aggregates primary literature into actionable summaries across therapy comparisons. Emphasize the unique capability to generate thousands of data point blends and rapid comparative analyses to support pricing, value dossiers, and health economics outcomes research (HEOR) needs for customers facing rigorous payer and regulatory requirements.

Advisory Network Leverage the Scientific Advisory Board and network of industry experts as a differentiator to build credibility with potential customers. Use advisory affiliations in outreach to establish trust, validate methodology, and open doors with large biotech and mid-tier pharma firms seeking evidence-based decision support.

Funding Stage Fit Prospects include early-stage companies with limited in-house HEOR capabilities and modest budgets, who would benefit from an AI-powered, scalable evidence platform. Highlight affordable entry models and potential expansion as the company grows, aligning with Evid Science’s current funding and revenue profile to drive incremental upsell opportunities.

Partnership Opportunities Explore collaborations with CROs, payer analytics groups, and health economics consultancies that can integrate Evid Science into their own data workflows. Joint offerings could extend reach, accelerate customer acquisition, and create recurring revenue through platform-enabled HEOR services and evidence generation as a service.